Approval · Notice of Compliance 37833 · 2026
EXELON: Notice of Compliance 37833
Issued July 2, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37833
- Date
- July 2, 2026
- Company
- Knight Therapeutics Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Change to existing indication: clarification to avoid confusion / Product Monograph reformatted to the Master Template / Update to the Product Monograph with new safety information
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EXELON | Not yet assigned | — |
Medicinal ingredients
- RIVASTIGMINE HYDROGEN TARTRATE 1.5 MG per CAP
- RIVASTIGMINE HYDROGEN TARTRATE 3 MG per CAP
- RIVASTIGMINE HYDROGEN TARTRATE 4.5 MG per CAP
- RIVASTIGMINE HYDROGEN TARTRATE 6 MG per CAP
- RIVASTIGMINE HYDROGEN TARTRATE 2 MG per ML